Ricoh Biosciences is a leading developer of advanced human iPSC-derived cell technologies that enable faster, more predictive drug discovery and therapeutic innovation. Using proprietary transcription-factor-based differentiation methods, the company produces high-quality, functional human cell types—including neurons, glia, oligodendrocytes, and other disease-relevant lineages—with speed and consistency.
Ricoh Biosciences’ integrated platforms support a wide range of applications, from target discovery and phenotypic screening to disease modeling and translational research. The company partners closely with biotech, pharmaceutical, and academic teams to design custom cell types, build specialized assays, and streamline workflows that reduce experimental variability and accelerate development timelines.
Driven by a mission of quality, innovation and collaboration, Ricoh Biosciences delivers accessible, reproducible human-cell technologies designed to transform how labs model human biology—with the goal of enabling new therapies by empowering scientific teams with more accurate and scalable human-cell models.
